Sultana B, et al. Incidence and prevalence of drug-resistant epilepsy: a systematic review and meta-analysis. Neurology. 2021;96(17):805–17.

Article  Google Scholar 

Cross JH, et al. Impact of fenfluramine on the expected SUDEP mortality rates in patients with Dravet syndrome. Seizure. 2021;93:154–9.

Article  Google Scholar 

Administration, F. D. (1973). FINTEPLA® (fenfluramine) oral solution, CIV. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212102s000lbl.pdf.

Fuller RW, Snoddy HD, Robertson DW. Mechanisms of effects of d-fenfluramine on brain serotonin metabolism in rats: uptake inhibition versus release. Pharmacol Biochem Behav. 1988;30(3):715–21.

CAS  Article  Google Scholar 

Zhang Y, et al. Pharmacological characterization of an antisense knockdown zebrafish model of Dravet syndrome: inhibition of epileptic seizures by the serotonin agonist fenfluramine. PLoS ONE. 2015;10(5):e0125898.

Article  Google Scholar 

Munro JF, Seaton DA, Duncan LJ. Treatment of refractory obesity with fenfluramine. BMJ. 1966;2(5514):624.

CAS  Article  Google Scholar 

Casaer P, Boel M. Fenfluramine as a potential antiepileptic drug. Epilepsia J Int League Against Epilepsy. 2002;43(2):205.

Google Scholar 

Connolly HM, et al. Valvular heart disease associated with fenfluramine–phentermine. N Engl J Med. 1997;337(9):581–8.

CAS  Article  Google Scholar 

Aicardi J, Gastaut H. Treatment of self-induced photosensitive epilepsy with fenfluramine. N Engl J Med. 1985;313(22):1419.

CAS  Article  Google Scholar 

Gastaut H, Zifkin B, Rufo M. Compulsive respiratory stereotypies in children with autistic features: polygraphic recording and treatment with fenfluramine. J Autism Dev Disord. 1987;17(3):391–406.

CAS  Article  Google Scholar 

Ceulemans B, et al. Successful use of fenfluramine as an add-on treatment for Dravet syndrome. Epilepsia. 2012;53(7):1131–9.

CAS  Article  Google Scholar 

Bonnycastle DD, Giarman NJ, Paasonen M. Anticonvulsant compounds and 5-hydroxy-tryptamine in rat brain. Br J Pharmacol Chemother. 1957;12(2):228–31.

CAS  Article  Google Scholar 

Jobe PC, Browning RA. The serotonergic and noradrenergic effects of antidepressant drugs are anticonvulsant, not proconvulsant. Epilepsy Behav. 2005;7(4):602–19.

Article  Google Scholar 

Nabbout R, et al. Fenfluramine for treatment-resistant seizures in patients with Dravet syndrome receiving stiripentol-inclusive regimens: a randomized clinical trial. JAMA Neurol. 2020;77(3):300–8.

Article  Google Scholar 

Sullivan J, et al. Fenfluramine responder analyses and numbers needed to treat: Translating epilepsy trial data into clinical practice. Eur J Paediatr Neurol. 2021;31:10–4.

CAS  Article  Google Scholar 

Lagae L, et al. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. The Lancet. 2019;394(10216):2243–54.

CAS  Article  Google Scholar 

Knupp KG, et al. Efficacy and safety of fenfluramine for the treatment of seizures associated with Lennox-Gastaut syndrome: a randomized clinical trial. JAMA Neurol. 2022;79(6):554–64.

Article  Google Scholar 

Serial echocardiographic assessment of patients with Dravet syndrome treated with fenfluramine (Fintepla®) for up to 3 years: no incidence of valvular heart disease or pulmonary artery hypertension.

Lai WW, et al. Cardiovascular safety of fenfluramine in the treatment of Dravet syndrome: analysis of an ongoing long-term open-label safety extension study. Epilepsia. 2020;61(11):2386–95.

CAS  Article  Google Scholar 

Sullivan J, Scheffer IE, Lagae L, Nabbout R, Pringsheim M, Talwar D, Polster T, Galer B, Lock M, Agarwal A, Gammaitoni A, Morrison G, Farfel G. Fenfluramine HCl (Fintepla®) provides long-term clinically meaningful reduction in seizure frequency: Analysis of an ongoing open-label extension study. Epilepsia. 2020 Nov;61(11):2396–404. https://doi.org/10.1111/epi.16722. Epub 2020 Oct 19. PMID: 33078386; PMCID: PMC7756901.

Specchio N, et al. Efficacy and safety of Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a real-world study. Epilepsia. 2020;61(11):2405–14.

CAS  Article  Google Scholar 

Sullivan J, et al. Fenfluramine significantly reduces day-to-day seizure burden by increasing number of seizure-free days and time between seizures in patients with Dravet syndrome: a time-to-event analysis. Epilepsia. 2022;63(1):130–8.

CAS  Article  Google Scholar